Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Strain-based vs LVEF-based Cardiotoxicity Prevention with Candesartan
NCT04429633Unknown
- Sponsor
- Samsung Medical Center
- Start
- Jul 2019
- Primary completion
- Jul 2022
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of candesartan in Cardiotoxicity (2 arms), sponsored by Samsung Medical Center. Primary endpoint: Left ventricular ejection fraction at 18 months. Status: unknown.
02
Drugs
candesartan
03
Conditions
Cardiotoxicity
Beyond the preview
Go deeper on NCT04429633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04429633.